- Last Updated on Friday, 19 August 2016 13:07
PHI and Boston Children’s Hospital enter evaluation agreement
PHI and Boston Children’s Hospital – a Harvard Medical School teaching hospital – have signed an agreement to evaluate PHI’s HoloMonitor® technology for applications in cell-based cancer research. During the evaluation period, PHI will provide Boston Children’s Hospital with HoloMonitor M4.5 instrumentation and technical support.
“The agreement with Boston Children’s Hospital and other opinion leading research institutions is a key component of our strategic marketing to establish HoloMonitor technology within preclinical research. We look forward to the results of the evaluation and to work with world class cancer researchers at the hospital,” said CEO Peter Egelberg.
About Boston Children’s Hospital
Big Pharma company orders third HoloMonitor
A current pharma customer recently ordered its third HoloMonitor® unit. The ordered configuration is the automated stage version of the HoloMonitor platform. The total retail price of the ordered units amounts to €90 000.
“The follow-up order from a world leading Swiss pharma company confirms the market potential within Big Pharma and the pharmaceutical industry in general. Big Pharma's interest shows that our HoloMonitor technology is rapidly becoming established and highlight the importance of our goal to create a Center of Excellence in the Basel area”, said CEO Peter Egelberg.
Swiss pharmaceutical industry
The pharmaceutical industry in Switzerland directly and indirectly employs close to 170 000 people and approximately contributes with 30% of the country's exports. Basel is the home of two largest Big Pharma companies in the world, Novartis and Roche.
- CEO commentary: Big Pharma, Big Data
- Big Pharma embraces HoloMonitor technology from Phase Holographic Imaging
HoloMonitor provide vital information to development of improved child cancer treatment
In 2010 under the leadership of Associate Professor David Gisselsson Nord at Lund University, research results developed in a collaboration between Lund University Hospital, the Institute of Cancer Research in London and Phase Holographic Imaging (PHI) where published. These pre-clinical research results – to which PHI’s HoloMonitor® technology provided vital information – have now led to an improved clinical treatment of malignant child cancer. The Swedish Cancer Foundation recently granted Gisselsson Nord additional funding to further develop the treatment.
“Last weeks $7.4 million grant to David Gisselsson Nord and other cancer researchers at Lund University will create additional opportunities for PHI and our local customers here in Lund, who predominantly are cancer researchers,” said CEO Peter Egelberg.
“We all like to see businesses we are working with succeed. But there is always something a bit more when the technology leads to something really special. I’m proud to be a part of PHI, both as adviser and shareholder” – Ron Lowy, Denver.
- David Gisselsson Nord Research Group
- New method for identifying most aggressive childhood cancers
- New method improves detection of malignant child cancer, interview in Swedish press
- Scientists at Lund University question leading theory of how cancer arise, interview in Swedish radio
- David Gisselsson and cancer research at Lund University receive 64 million kronor donation (in Swedish)
- Child cancer research awarded by the Fernström foundation (in Swedish)
- Article from 2010 in Proceedings of the National Academy of Sciences (PNAS)
PHI achieves market acceptance goals
Prior to the company’s IPO in early 2014, three market acceptance goals were set out to be achieved by the end of 2015:
- 50 units in operation at customers and key opinion leaders,
- collaboration agreements with 8 key opinion leaders and
- the company’s main product HoloMonitor® M4 shall be manufactured in series production.
These goals have now been achieved:
- The 50th HoloMonitor unit was recently installed at University of California, San Francisco. The installation is part of a previously announced collaboration to accelerate skin cancer research at the university.
- Among others, strategic collaboration agreements are ongoing with research groups at:
- Harvard University, Boston
- Northeastern University, Boston
- 2 × Karolinska Institute, Stockholm
- University of California, San Francisco
- Florida International University, Miami
- German Cancer Research Center, Heidelberg
- Korea Research Institute of Bioscience and Biotechnology, Daejeon
- An initial batch of HoloMonitor M4.5 units is currently being manufactured according to the agreement with the company’s contract manufacturer Optronic. In the batch, the 100th HoloMonitor M4 unit will be manufactured. To date over 80 HoloMonitor units have been sold and delivered.
“We can definitely see the market respond to our strategic collaborations and the 50 units in operation. To meet the rising demand with a high gross margin, production of the HoloMonitor M4.5 base unit has been moved to series production. This will allow us to focus our engineering resources on implementing the design changes needed to also manufacture the M4’s motorized stage in series production with the same high gross margin,” said CEO Peter Egelberg.
“The motorized stage dramatically increases our revenues and is crucial when addressing the Big Pharma market, as it enables automation of applications in what is known in the industry as high-content screening. The current design is flexible, which was important during the evaluation phase, but costly to manufacture. The feedback received through initial sales to Big Pharma and others now allow us to finalize and adapt the design of the motorized stage for series production, and thereby reduce the manufacturing cost.”
PHI invited to speak at world leading scientific event
Phase Holographic Imaging has been invited to give an invited talk in February at the world’s leading scientific event for biomedical optics, BiOS 2016 in San Francisco. For the second consecutive year BiOS hosts a conference exclusively dedicated to holographic microscopy and phase imaging. At the conference, applications of HoloMonitor® technology in academia and the pharmaceutical industry will be presented.
“The size and length of the four day conference reflects the accelerating interest in holographic microscopy and its applications. It is an honor to be invited to speak about our HoloMonitor technology at this prestigious scientific conference. The invitation confirm our growing international reputation and our position at the forefront of the rapidly expanding cell analysis market”, said CEO Peter Egelberg.
Big Pharma embraces HoloMonitor technology from PHI
Upon completion of an extensive evaluation in early September one of the top pharmaceutical companies in the world has decided to acquire two HoloMonitor® instruments. The ordered configuration is an automated version of the HoloMonitor platform. The total retail price of the orders amounts to €60 000.
“The pharmaceutical industry uses what is known in the industry as high-content screening to select drug candidates from several 100 000 chemical substances. The orders from the leading Swiss pharma company are tremendously important for the company’s future and confirm the potential of HoloMonitor technology in high-content screening. Valuable feedback from the pharma industry will enable us to further improve our proprietary technology for more realistic drug characterization. Various reports value the global high-content screening market to 500-1 100 million USD annually”, said CEO Peter Egelberg.
HoloMonitor technology help researchers fight ovarian cancer
Ovarian cancer is one of the deadliest forms of cancer. Researchers at the Center of Excellence for Holographic Imaging at Northeastern University in Boston have used HoloMonitor technology to study how the immune system can be stimulated to fight this deadly cancer form. The research results have been published in Journal of Clinical & Cellular Immunology. The article is the first scientific article to be published in a series of articles from Northeastern University in which HoloMonitor technology play a key role.
“The collaboration with Northeastern University is a huge success. Together with our advisers, the researchers at Northeastern have done a fantastic job in chiseling out new applications for our HoloMonitor technology. The success of the collaboration means that PHI has established a strategic presence in Boston – the Capital of life science research. This permanent presence allows us to market our products to both customers and leading industry players in ways not possible from Sweden”, said CEO Peter Egelberg.
Phase Holographic Imaging receives first order from United Kingdom after exhibition
In June Phase Holographic Imaging (PHI) exhibited HoloMonitor® M4.5 at the CYTO 2015 conference in Glasgow. In addition, results from the development work of HoloMonitor® M5 were presented. This work is funded by the Swedish Research Council and is conducted in collaboration with Lund University. The Swedish Research Council is an authority within the Ministry of Education and Research.
The annual CYTO conferences mainly address industry professionals. As part of PHI’s market expansion, the main objective of PHI’s presence was to raise industry awareness by showcasing the HoloMonitor products.
The PHI stand was strategically situated next to Thermo-Fisher Scientific, leading to a large number of inquisitive visits from Thermo-Fisher and other major industry stakeholders. A number of potential customers visited the PHI stand, among them the researchers from University of Edinburgh who recently ordered a HoloMonitor M4.5 instrument.
“This order is an important reference order, as it will be our first unit in operation in the UK. University of Edinburgh is one of the leading research institutions in the UK. They will be a valuable reference for our UK representative, which we currently are in the process of selecting”, says CEO Peter Egelberg.
A special lecture was given by Eric Betzig – “Imaging Life at High Spatiotemporal Resolution”. Eric Betzig was awarded the Nobel Prize in 2014 for co-inventing the super resolving fluorescent light microscope, a very advanced form of fluorescence microscopy. Notably a scientific tutorial on quantitative, non-invasive, imaging for cell analysis was held. These events demonstrate the growing interest in time-resolved and non-invasive cell analysis approaches, the cornerstones of PHI’s products and technology.
“It is very encouraging to see the industry’s increasing interest in our products and time-lapse cytometry. This is driven by a growing number of scientists realizing that quantifying over time is crucial for a full understanding of cell systems and multicellular organisms. It is not sufficient to look at some snapshots images. It is as hopeless as understanding the chain of events in a soccer game by looking at some still images the day after.”
About HoloMonitor M5
Light activated fluorescent chemical labels are commonly used by cell biologists to detect biochemical compounds. However, fluorescent labels are toxic, especially when activated. By combining HoloMonitor technology with fluorescence detection capabilities, the activation of fluorescent labels can be dramatically reduced to minimize the toxic effect on cell behavior.
The CYTO conferences are organized by the International Society for Advancement of Cytometry and focus on cutting-edge cytometry to open new horizons in biology on the level of individual cells. Recent developments in flow cytometry, advanced microscopy, data evaluation and fluorescent labels enable a new understanding of basic molecular mechanisms and the diseases that plague humanity.
Florida International University and PHI collaborate to fight cancer
Florida International University (FIU) and PHI have entered a collaboration agreement. To determine the scope of a long-term collaboration, PHI will initially provide FIU with a HoloMonitor instrument during 4 months. The instrument will be used to characterize breast cancer stem cells.
Additional information about the collaboration has been published on the university’s website, breakthroughs.fiu.edu.
PHI provides second HoloMonitor® to University of California, San Francisco to accelerate skin cancer research
PHI has entered into a collaboration agreement with University of California, San Francisco (UCSF) to accelerate ongoing skin cancer research at UCSF. Under the 11 month agreement, PHI will provide a HoloMonitor® M4.5 with a motorized stage to supplement the instrument which UCSF purchased previously for preclinical research in the field.
“A key strategic goal for the US market is to establish HoloMonitor technology through Centers of Excellence in the Boston, San Diego and San Francisco areas. With its five Nobel laureates, UCSF is widely regarded as one of the world's leading universities in health sciences. The collaboration with UCSF is an exciting step towards establishing a Center of Excellence in the San Francisco area”, says CEO Peter Egelberg.
Centers of Excellence
The purpose of PHI’s Centers of Excellence program is to create industry visibility in life science hotspots such as London, Basel, Heidelberg, San Diego, San Francisco, Boston and Tokyo. A Center of Excellence is an application development hub and educational resource providing training programs for scientists using PHI’s HoloMonitor technology. A first Center of Excellence has been established at Northeastern University in Boston.
HoloMonitor technology shows versatility as important tool in nanotechnology research
Researchers at University of Pannonia in Hungary recently published a scientific study where HoloMonitor technology from Phase Holographic Imaging (PHI) is used to study cell growth on nanostructures. The study confirms that HoloMonitor technology has a unique potential to become an important tool for investigating cellular behavior on nanostructures under the influence of pharmaceuticals.
In 2014 Henrik Persson at the Department of Solid State Physics at Lund University published his doctoral thesis “Nanowires in Cell Biology”. A substantial part of the thesis is based on measurements obtained using PHI’s HoloMonitor technology.
“Recently the department in Lund ordered their second HoloMonitor unit for applications in nanotechnology. The independent study by the researchers at University of Pannonia confirms HoloMonitor’s unique ability to analyze cells growing on nanostructures,”, says CEO Peter Egelberg.
“When the researcher at University of Pannonia purchased their HoloMonitor our motorized sample stage was not available. We can now offer a motorized stage that addresses the issues discussed in the article and are excited about this new market opportunity.”
Germany’s largest biomedical research institute foster the use of PHI technology
German Cancer Research Center (DKFZ) in Heidelberg and PHI have signed a collaboration agreement, to foster the use of HoloMonitor technology at DKFZ. A HoloMonitor M4 with a motorized XY-stage will be centrally installed at the Imaging and Cytometry Core Facility and made available to the over 1 000 cancer researchers at DKFZ.
“DKFZ is one of the leading cancer research centers in Europe, if not the leading. Our strategy is to continue to demonstrate the benefits of HoloMonitor technology with leading research institutions and key opinion leaders on the forefront of cancer research. A key goal for PHI is to establish 8 strategic partnerships with leading research institutions before the end of 2015. With this agreement, 6 such agreements have now been signed”, says CEO Peter Egelberg.
PHI expands into Australia and respiratory research
In April Phase Holographic Imaging (PHI) had outstanding orders of approximately 2 MSEK, consisting of 13 HoloMonitor M4 units and 15 orders for the recently launched motorized stage. A portion of these units have now been delivered. Among others, a HoloMonitor M4 with motorized stage has been delivered to one of the leading institutes for respiratory research in Australia – the Woolcock Institute of Medical Research.
To improve the understanding of the mechanisms behind asthma the Respiratory Cellular and Molecular Biology Group will measure volume changes in respiratory muscle cells using PHI’s HoloMonitor technology. The ability to effortlessly measure changes in cell volume is one of the unique and innovative advantages of HoloMonitor technology.
“We see a limited value in reporting individual orders and deliveries that lack strategic value to our investors. However, this installation is of strategic value as it is our first instrument on the Australian continent. Additionally, the order opens up a new market for us – respiratory research”, says Peter Egelberg, CEO of PHI.
PHI expands collaboration with Karolinska Institutet
Karolinska Institutet and PHI have entered a second research agreement. Assistant Professor Lindqvist’s research group studies how DNA-damage affects human cell division. To facilitate this research, the group actively develops novel microscopy-based techniques.
PHI will support Professor Lindqvist’s research by providing HoloMonitor instrument, training and support during six months. The research group will supply personnel and research material to execute the agreed research plan. The research results will be published in selected scientific journals.
Almi grants a 6 million SEK credit to Phase Holographic Imaging
In cooperation with the European Investment Fund Almi Företagspartner Skåne has granted a 6 million SEK credit to Phase Holographic Imaging (PHI), on favourable terms.
“Our cooperation with PHI goes more than ten years back. It has been very stimulating to follow PHI during these years. The new loan allow us to continue to support and follow PHI”, says Göran Alvek, financing manager, Almi Skåne.
”The support from Almi has been very important for PHI during the research and development phase. We are very pleased that Almi will support us in our expansion phase as well” says Peter Egelberg, founder and CEO of PHI.
Almi offers advisory services, loans and venture capital through all phases of the establishment of a business – from idea to successful company. This includes ideas with potential for growth in the early stages as well as existing companies that are investing in growth and expansion. Almi Företagspartner AB is owned by the Swedish government and is the parent company of a group consisting of 16 regional subsidiaries, Almi Invest AB and IFS Rådgivning AB. With 40 offices across Sweden, we are always close to our customers.
PHI Exports to China Continue to Rise
PHI has received a large order for HoloMonitor M4 units. The units will be delivered to PHI’s Chinese distributor during the coming 12 months on a continuous basis. Together with currently outstanding orders, this new order will give additional revenues of over 1.7 MSEK.
“Upon completion of the installation of the recently ordered units, the total installed base will reach over 40 units worldwide. This brings us very close to our goal of having 50 units in operation before the end of 2015”, says Peter Egelberg, CEO of PHI.
Research based on HoloMonitor technology to be present at the annual meeting of the American Association for Cancer Research
Northeastern University scientists, associated with the Holographic Imaging Cytometry Program of Excellence, have been selected to present their research results at three occasions at the annual meeting of the American Association for Cancer Research (AACR) in April 2015. In their research, the scientists have used the HoloMonitor M4 time-lapse cytometer from Phase Holographic Imaging to visualize and characterize cellular behavior.
AACR support all forms of research on more than 200 types of cancer. Among its 33 000 members are the world's leading cancer researchers, including 40 Nobel laureates. In 2014 over 18 000 researchers and other professionals in the cancer field attended the annual meeting of AACR.
About Holographic Imaging Cytometry Program of Excellence
The Holographic Imaging Cytometry Program of Excellence is an application development hub and educational resource providing training programs for scientists using time-lapse cytometry. The Program is located at Northeastern University in Boston Massachusetts and was jointly created by Northeastern University and Phase Holographic Imaging.
PHI signs agreement with researchers at Karolinska Institutet
Effective from February 1, 2015, Professor Pontus Aspenström at Karolinska Institutet and Phase Holographic Imaging have entered a research agreement. The research goal of the group is to identify how cell communication contributes to tumor growth and spreading.
PHI will support this research by providing the research group with instrumentation, training and technical support during seven months. During this period, Professor Aspenström’s group will supply the personnel and research material needed to execute the agreed research plan. The research results will be published in selected scientific journals.
“Our instruments make it possible to quantitatively track individual cells. This ground-breaking technology is essential to better understand tumor growth and spreading. It is very encouraging that the development work, which began in Professor Stina Oredsson’s laboratory at Lund University, is increasingly being recognized by other cancer researcher, both nationally and internationally.”, concludes Peter Egelberg, CEO and founder of PHI.
Northeastern University’s Holographic Imaging Program of Excellence Webpage Launched
A webpage dedicated to the activities of the Holographic Imaging Cytometry Program of Excellence in Boston Mass. was launched on January 27, 2015. The Holographic Imaging Cytometry Program of Excellence is a partnership between Northeastern University and Phase Holographic Imaging to create an application development hub and educational resource for holographic imaging cytometry.
The webpage will serve as the Program’s communication channel to assist in establishing a network of collaborations utilizing holographic imaging cytometry, in the greater Boston-area. It will provide updates on studies employing HoloMonitor technology and coordinate local scientific meetings.
Highlights of the Program
- The efficacy of a recently developed drug delivery system, by Northeastern University scientists, was shown using HoloMonitor M4. Read application note
- Presentations by Northeastern University scientists have been submitted for presentation at the American Association for Cancer Research annual meeting – April 2015, Philadelphia.
- Holographic Time-lapse Imaging Cytometry Symposium – summer 2015, Boston.
PHI continues expansion in China
In November PHI’s Chinese distributor, Bio-Sun, received customer orders of three more HoloMonitor M3 units. The units have now been finalized and will shortly be shipped to Bio-Sun for immediate installation.
Among the new customers are the School of Basic Medicine, Henan University of Traditional Chinese Medicine and the Institute of Bioengineering, Zhejiang University. These orders continue to validate the utility of PHI HoloMonitor technology across the spectrum of life science applications.